A Retrospective Analysis of the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors at The Ottawa Hospital Cancer Center over the Last Decade Including COVID-19 Pandemic Period.

IF 2.5 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2024-09-25 DOI:10.1159/000540907

Mohammad Alrehaili, William J Phillips, Tim Asmis, Michael Vickers, Horia Marginean, Rachel Goodwin

{"title":"A Retrospective Analysis of the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors at The Ottawa Hospital Cancer Center over the Last Decade Including COVID-19 Pandemic Period.","authors":"Mohammad Alrehaili, William J Phillips, Tim Asmis, Michael Vickers, Horia Marginean, Rachel Goodwin","doi":"10.1159/000540907","DOIUrl":null,"url":null,"abstract":"Introduction: The incidence of neuroendocrine tumors (NETs) is rising. Our objective was to assess trends in gastroenteropancreatic (GEP)-NETs diagnosis (June 2010 to June 2021) at TOHCC and to explore whether early COVID-19 pandemic data impacted these trends.Methods: This was a single-center retrospective chart review of data collected from June 2010 to June 2021. We searched all databases, including OACIS/EPIC, PACS, and OPIS and found 647 GEP-NET patients. Descriptive analyses were performed using frequencies and related percentages.Results: Of 647 patients with GEP-NETs, the small bowel was the most common primary location (n = 210, 32.4%), followed by the pancreas (n = 118, 18.2%), and unknown primary location (n = 99, 15.3%). Most of the cases were classified as metastatic or locally advanced at the initial presentation. There has been no significant variation in the frequency distribution of these cases over the last decade. Stages 1 and 2 were found in 158 cases (23.8%), and lower gastrointestinal (GI) tumors were the most common disease among them (n = 88, 55.7%). There were 5 lower GI cases in 2010-2011 and average number per registration year was 5.5 until 2016-2017, after which time the number of cases increased to 10, 15, 11, and 13 during the last 4 years. Regarding early-stage pancreatic and upper GI NETs, the total number of cases was 52 (32.9%) and 18 (11.4%), respectively. The average number of cases per registration year for pancreatic tumors was 4.7, while that for upper GI tumors was 1.6 over the last decade.Discussion: At our center, most GEP-NETs presented in an advanced setting. Small bowel is the most common location overall. The incidence of early-stage disease has increased. Disease detection for all GEP-NETs was consistent throughout the last decade, except for the lower GI cases that have increased since mid-2017, perhaps reflecting the adoption of Ontario FIT testing. Despite endoscopy closures and disruption of some diagnostic services during the pandemic, cases of GEP-NETs for all stages did not decrease.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540907","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The incidence of neuroendocrine tumors (NETs) is rising. Our objective was to assess trends in gastroenteropancreatic (GEP)-NETs diagnosis (June 2010 to June 2021) at TOHCC and to explore whether early COVID-19 pandemic data impacted these trends.

Methods: This was a single-center retrospective chart review of data collected from June 2010 to June 2021. We searched all databases, including OACIS/EPIC, PACS, and OPIS and found 647 GEP-NET patients. Descriptive analyses were performed using frequencies and related percentages.

Results: Of 647 patients with GEP-NETs, the small bowel was the most common primary location (n = 210, 32.4%), followed by the pancreas (n = 118, 18.2%), and unknown primary location (n = 99, 15.3%). Most of the cases were classified as metastatic or locally advanced at the initial presentation. There has been no significant variation in the frequency distribution of these cases over the last decade. Stages 1 and 2 were found in 158 cases (23.8%), and lower gastrointestinal (GI) tumors were the most common disease among them (n = 88, 55.7%). There were 5 lower GI cases in 2010-2011 and average number per registration year was 5.5 until 2016-2017, after which time the number of cases increased to 10, 15, 11, and 13 during the last 4 years. Regarding early-stage pancreatic and upper GI NETs, the total number of cases was 52 (32.9%) and 18 (11.4%), respectively. The average number of cases per registration year for pancreatic tumors was 4.7, while that for upper GI tumors was 1.6 over the last decade.

Discussion: At our center, most GEP-NETs presented in an advanced setting. Small bowel is the most common location overall. The incidence of early-stage disease has increased. Disease detection for all GEP-NETs was consistent throughout the last decade, except for the lower GI cases that have increased since mid-2017, perhaps reflecting the adoption of Ontario FIT testing. Despite endoscopy closures and disruption of some diagnostic services during the pandemic, cases of GEP-NETs for all stages did not decrease.

查看原文本刊更多论文

对渥太华医院癌症中心（TOHCC）过去十年（包括 COVID-19 大流行期间）胃肠胰神经内分泌肿瘤（GEP-NET）诊断情况的回顾性分析。

导言NET的发病率正在上升。我们的目的是评估 TOHCC 的 GEP-NETs 诊断趋势（2010 年 6 月至 2021 年 6 月），并探讨早期 COVID-19 大流行数据是否会影响这些趋势：这是对 2010 年 6 月至 2021 年 6 月期间收集的数据进行的单中心回顾性病历审查。我们搜索了所有数据库，包括 OACIS/EPIC、PACS 和 OPIS，发现了 647 名 GEP-NET 患者。我们使用频率和相关百分比进行了描述性分析：在647例GEP-NET患者中，小肠是最常见的原发部位（210例，32.4%），其次是胰腺（118例，18.2%）和原发部位不明（99例，15.3%）。大多数病例在初次发病时被归类为转移性或局部晚期。在过去十年中，这些病例的频率分布没有明显变化。158例（23.8%）患者为1期和2期，其中下消化道肿瘤最为常见（88例，55.7%）。2010-2011年，下消化道肿瘤病例为5例，2016-2017年之前，平均每登记年病例数为5.5例，之后的4年间，病例数分别增至10例、15例、11例和13例。早期胰腺 NET 和上消化道 NET 的病例总数分别为 52 例（32.9%）和 18 例（11.4%）。在过去十年中，胰腺肿瘤的平均登记年病例数为4.7例，而上消化道肿瘤的平均登记年病例数为1.6例：讨论：在我们中心，大多数 GEP-NET 都是晚期病例。小肠是最常见的部位。早期疾病的发病率有所上升。所有 GEP-NET 的疾病检出率在过去十年中保持一致，但下消化道病例自 2017 年年中以来有所增加，这或许反映了安大略省 FIT 检测的采用。尽管大流行期间关闭了内窥镜检查并中断了一些诊断服务，但各阶段的 GEP-NET 病例并未减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.